LNTH vs NTLA
Lantheus Holdings, Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | LNTH | NTLA |
|---|---|---|
| Revenue | $1.5B | $67.7M |
| Net income | $233.6M | $-412.7M |
| Gross margin | 61.1% | · |
| Net margin | 15.2% | −609.9% |
| Return on equity | 21.4% | −53.5% |
| Diluted EPS | $3.41 | −$3.81 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | $-395.9M |
| Equity | $1.1B | $671.4M |
| Net debt / equity | 0.19× | · |
| Current ratio | 2.70× | 5.08× |
| Revenue CAGR 5y | 35.3% | 3.1% |
| Profit CAGR 5y | · | · |
LNTH bills 22.8× the revenue of NTLA, and NTLA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | LNTH | NTLA |
|---|---|---|
| FY2025 | $1.5B | $67.7M |
| FY2024 | $1.5B | $57.9M |
| FY2023 | $1.3B | $36.3M |
| FY2022 | $935.1M | $52.1M |
| FY2021 | $425.2M | $33.1M |
| FY2020 | $339.4M | $58.0M |
| FY2019 | $347.3M | $43.1M |
| FY2018 | $343.4M | $30.4M |
| FY2017 | $331.4M | $26.1M |
| FY2016 | $301.9M | $16.5M |
Bottom line
| Fiscal year | LNTH | NTLA |
|---|---|---|
| FY2025 | $233.6M | $-412.7M |
| FY2024 | $312.4M | $-519.0M |
| FY2023 | $326.7M | $-481.2M |
| FY2022 | $28.1M | $-474.2M |
| FY2021 | $-71.3M | $-267.9M |
| FY2020 | $-13.5M | $-134.2M |
| FY2019 | $31.7M | $-474.2M |
| FY2018 | $40.5M | $-85.3M |
| FY2017 | $123.4M | $-67.5M |
| FY2016 | $26.8M | $-31.6M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$1,473,938,000 | LNTH |
| FY2024 | +$1,476,033,000 | LNTH |
| FY2023 | +$1,260,154,000 | LNTH |
| FY2022 | +$882,940,000 | LNTH |
| FY2021 | +$392,155,000 | LNTH |
| FY2020 | +$281,416,000 | LNTH |
| FY2019 | +$304,234,000 | LNTH |
| FY2018 | +$312,940,000 | LNTH |
| FY2017 | +$305,261,000 | LNTH |
| FY2016 | +$285,374,000 | LNTH |
LNTH has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 13 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +625.0 pp | LNTH |
| FY2024 | +917.1 pp | LNTH |
| FY2023 | +1351.7 pp | LNTH |
| FY2022 | +912.8 pp | LNTH |
| FY2021 | +793.7 pp | LNTH |
| FY2020 | +227.5 pp | LNTH |
| FY2019 | +240.0 pp | LNTH |
| FY2018 | +292.2 pp | LNTH |
| FY2017 | +295.9 pp | LNTH |
LNTH has kept the higher net margin in every one of these 9 fiscal years.
9 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's net margin has been more volatile than LNTH's over the 9 comparable fiscal years — 371.8 percentage points of standard deviation against 15.1.
9 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LNTH led in net margin in every one of the 9 comparable fiscal years — a structural lead, not a recent swing.
9 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's return on equity has been more volatile than LNTH's over the 8 comparable fiscal years — 44.4 percentage points of standard deviation against 30.3.
8 of 9 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LNTH led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 9 comparable fiscal years — a year missing data on either side is not counted.